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Abstract
Introduction: Systemic B-cell depletion and clinical remission of the systemic effects of cryoglobulins have already
been achieved using rituximab in hepatitis C virus-positive immunocompetent patients. Conversely, to the best of
our knowledge there are no reports in the literature regarding the use of rituximab in hepatitis B virus-associated
cryoglobulinemia.
Case presentation: We report here the case of a 60-year-old Caucasian man who presented with hepatitis B virus-
associated type II cryoglobulinemia with severe multisystem disease, including membranoproliferative
glomerulonephritis with acute renal failure. The vasculitis was refractory to conventional and antiviral therapy but
rituximab use led to a fall in cryoglobulin levels and disease control. The B-cell depletion was safe and efficient to
induce a complete remission of the disease.
Conclusion: Our case highlights the benefit and the efficacy of rituximab in association with antiviral therapy in
small vessel vasculitis related to hepatitis B virus-associated mixed cryoglobulinemia.
Introduction
Cryoglobulinemia is a disease characterized by immuno-
globulins that are soluble at 37°C, precipitate in the
cold, and redissolve when heated. Cryoglobulins may
precipitate in the microvasculature and are usually asso-
ciated with inflammatory manifestations in the vessel
walls [1]. Three types of cryoglobulinemia are recog-
nized, according to the cryoprecipitated immunoglobu-
lins. In type I, a monoclonal immunoglobulin is
identified. In types II and III, called mixed cryoglobuli-
nemia (MC), two classes of immunoglobulins are pre-
sent: a polyclonal immunoglobulin G (IgG) and an
immunoglobulin M (IgM) with rheumatoid factor activ-
ity, the latter either monoclonal in type II or polyclonal
in type III. Type II cryoglobulinemia is often associated
with hepatitis C virus (HCV) infection [2] and is less
common with hepatitis B virus (HBV) infection. The
few historical series of cryoglobulinemia with HBV
infection reported in the literature were not able to
determine the role of co-infection with HCV [3-5]. The
disease expression is variable, ranging from mild clinical
symptoms (purpura, arthralgia) to fulminant life-threa-
tening complications (glomerulonephritis, widespread
vasculitis). Conventional treatment of MC vasculitis is
not yet standardized, but in the absence of viral infec-
tion, this treatment typically involves corticosteroids,
immunosuppressive drugs and plasma exchange. A
recent study has highlighted the efficacy and the ster-
oid-sparing effect of rituximab in non-viral cryoglobuli-
nemia vasculitis, but has also reported the occurrence of
severe infections [6]. Treatment of HCV-MC vasculitis
may target either the viral trigger (HCV) or the down-
stream B-cell arm of autoimmunity [7,8]. Few data are
available for the treatment of the HBV-associated cryo-
globulinemia [9]. Even if rituximab was shown to be a
cause of fatal hepatitis due to B virus reactivation, this
drug could be a promising treatment in this kind of
vasculitis.
We report here a case of HBV-associated type II cryo-
globulinemia with severe multisystem disease, which
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agents but in which rituximab led to a fall in cryoglobu-
lin levels and disease control.
Case presentation
A 60-year-old Caucasian male patient with a six-month
history of relapsing rash, sicca syndrome, abdominal
pain and peripheral edema was admitted to hospital for
further investigation. A physical examination showed
bilateral edema and hypertension (blood pressure 200/
108 mmHg), while a chest X-ray confirmed bilateral
pleural effusions and showed an enlarged cardiac silhou-
ette. There was marked (4+) pitting edema of both fore-
arms and legs, extending up to his thighs. A neurologic
examination was normal. A cardiac examination
revealed a systolic murmur in the left side of his ster-
num. Raised purpuric lesions were present on his left
leg. His right third proximal interphalangeal joint, left
elbow and right knee were slightly warm to the touch at
examination, without effusion. Our patient described
symptoms that suggested the presence of Raynaud’s
phenomenon.
Abnormal laboratory results included a platelet count
of 123 × 10
3/μL, serum creatinine level of 490 μmol/L,
proteinuria with 8.2 g/24 h, hematuria and hypoalbumi-
nemia (18 g/L). Cryoglobulins were positive, with a
cryocrit of 6% containing IgG at 510 mg/dL and a
monoclonal IgM band at 680 mg/dL, elevated rheuma-
toid factor (5995 IU/mL) and hypocomplementemia (C3
level, 0.21 g/L, normal range 0.80 g/L to 2.14 g/L; C4,
0.02 g/L, normal range 0.13 g/L to 0.60 g/L). Viral
screening was negative for hepatitis C by serology and
polymerase chain reaction. A test for hepatitis B surface
antigen was positive while a test for hepatitis B surface
antibody was negative. The hepatitis B viral load was
slightly positive at 100,000 copies/mL. A test for hepati-
tis B e-antigen was negative, and a test for hepatitis B e-
antibody was positive, suggesting the possibility of muta-
tion. The first renal biopsy findings revealed acute renal
vasculitis characterized by segmental fibrinoid necrosis
associated with 35% crescents. Diffuse mesangial endo-
capillary proliferation and inflammatory cells infiltration
were observed as well, consistent with cryoglobulinemic
glomerulonephritis (Figure 1). No immunofluorescence
study was done because of a lack of material. A skin
biopsy specimen of a purpuric lesion showed leukocyto-
clastic vasculitis. A biopsy specimen of his bone marrow
was normal.
A diagnosis of MC vasculitis with glomerulonephritis
was made and treatment initiated with intravenous
methylprednisolone (1 g/day for three days) and oral
prednisolone (60 mg daily), thereafter associated with
antiviral therapy (lamivudine). One week later, because
of gradual deterioration in renal function (serum
creatinine 620 μmol/L; urine protein 12 g/24 h) and a
falling hemoglobin level (6.9 g/dL), our patient under-
went plasma exchange (60 mL/kg/day for 15 days). The
subsequent course was complicated by severe sepsis due
to Pseudomonas aeruginosa, requiring intensive care and
dialysis.
Despite further plasma exchange, the vasculitis and
renal failure did not improve. A diagnosis of polyarteri-
tis nodosa was then suspected and cyclophosphamide
was used (0.5 g/m
2 monthly, six times) but a second
renal biopsy then showed type I membranoproliferative
glomerulonephritis (lobular mesangial proliferation, dou-
ble-contours and persistence of inflammatory cells infil-
tration), finally confirming a diagnosis of MC vasculitis.
Immunofluorescence staining showed IgM and C3 dis-
continuous granular deposits along the peripheral glo-
merular loops (Figure 2).
Cyclophosphamide was stopped, antiviral therapy was
switched from lamivudine to entecavir and our patient
then received a monoclonal anti-CD20 antibody, rituxi-
mab, 375 mg/m
2, as four-weekly infusions with oral pre-
dnisolone (25 mg/day). This led to a depletion of
circulating B-cells. His purpura remitted, the proteinuria
declined (0.56 g/day) and his renal function returned to
normal (creatininemia, 95 μmol/L). His cryocrit and
rheumatoid factor fell and complement levels rose. The
HBV viral load became undetectable. Mycophenolic acid
was begun after the four rituximab infusions as
Figure 1 First renal biopsy specimen. On the first biopsy the
glomerulus is globally hypercellular, with numerous intracapillary
mononuclear cells. A small artery has intimal thickening with
scattered infiltrating mononuclear cells, together with segmental
medial disruption and perivascular fibrosis, indicating vasculitis
(hematoxylin and eosin). This renal vasculitis is characterized by
segmental fibrinoid necrosis associated with 35% crescents. Diffuse
mesangial endocapillary proliferation and inflammatory cells
infiltration is observed as well, consistent with crescentic
glomerulonephritis.
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charged from hospital. One year after his initial admis-
sion, our patient felt well, and took medication
including mycophenolic acid, entecavir and irbesartan.
The creatininemia level was within normal range at 88
μmol/L and the level of rheumatoid factor remained
negative. The HBV viral load remained undetectable.
Discussion
Cryoglobulinemia is a heterogeneous disease character-
ized by the appearance of cryoglobulin, which precipi-
tates at low temperature in serum, deposits in
microvessels and suggests angiitis, leading to manifesta-
tions including skin ulcer, purpura and glomerulone-
phritis [10]. In chronic viral infection, such as HBV and
HCV infection, cryoglobulin consists in heterogeneous
antigen-antibody immune complexes containing virus
particles, IgG and IgM [11]. In our patient, the initial
HBV viral load was probably low because virus particles
were trapped in the cryoglobulins, as described in
HCV-associated MC. Suppression of viral replication
resolves cryoglobulinemia in some cases. For instance,
interferon and B-cell depletion therapy for HCV is
reported to improve cryoglobulinemia and vasculitis
[12]. However, lamivudine given for exacerbated chronic
hepatitis B did not improve the cryoglobulinemic vascu-
litis. On the other hand, rituximab is a chimeric mono-
clonal antibody that binds to the B-cell surface antigen
CD20. It interferes with monoclonal IgM production,
cryoglobulin synthesis and renal deposition of immune
complexes [13]. Rituximab infusion results in rapid B-
cell depletion in the peripheral blood. To the best of
our knowledge, there has been no report in the litera-
ture on the use of rituximab in HBV presenting with
MC. Our case remains very striking because several
investigators have reported fulminant hepatitis caused
by HBV reactivation [14] after rituximab therapy.
Some researchers have also reported prophylaxis using
lamivudine for HBV infection while the patients were
also receiving rituximab. Indeed, HBV reactivation dur-
ing the fourth to sixth (or between the third and fifth)
cycles of rituximab treatment was reported, and one
study markedly documented late HBV reactivation sev-
eral months after the completion of rituximab treat-
ment [15].
As the use of rituximab appears to be a safe and effec-
tive therapeutic option in symptomatic patients with
HCV-associated MC with signs of systemic vasculitis,
we decided to treat our patient with rituximab along
with a highly active antiviral therapy such as entecavir.
Conclusions
Rituximab can represent a safe and effective alternative
to standard immunosuppression in HBV-associated type
II MC, especially with severe manifestations such as dif-
fuse membranoproliferative glomerulonephritis and
when the antiviral therapy is not efficient in improving
the kidney disease.
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Figure 2 Second renal biopsy specimen. A second renal biopsy
was performed at the end of the treatment (six months of antiviral
therapy and 24 plasma exchange therapies). The
immunofluorescence pattern shows intense massive staining of the
deposits totally filling the capillary lumina. Faint and irregular
parietal deposits also are present along peripheral glomerular loops.
The components of mixed cryoglobulinemia immunoglobulin M,
usually associated with C3, are the most frequently found
immunoreactants.
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